Acute myeloid leukemia Market Report

1
EPIDEMIOLOGY
Market Drivers Prevalence Rate Growing Incidence and Prevalence Rates About 20,800 people will Increasing Elderly Population be diagnosed with AML. Increasing RD Activity Mortality Rate Market Challenges About 11,220 people will die from AML. Limited awareness results in delayed diagnosis inadequate treatment decisions. High cost associated with treatment.
It accounts for about 1 out of 3 leukemias in adults. Insight It tends to have a higher incidence in older adults. 80 (approx.) of new cases occur in individuals aged 60 and above
COMPETITIVE LANDSCAPE
Key Players/Approved Drugs
Company Generic Name Brand Name Mechanism of Action (MoA) Route of Administration (RoA) Headquarters






Inhibits multiple receptor tyrosine
kinases CD33-directed antibody- drug conjugate
(ADC) Small molecule inhibitor of the
isocitrate dehydrogenase 2 (IDH2)
enzyme Isocitrate dehydrogenase- 1 (IDH1)
inhibitor Isocitrate dehydrogenase- 1 (IDH1)
inhibitor BCL-2 inhibitor
Midostaurin Gemtuzumab ozogamicin Enasidenib
Ivosidenib Olutasidenib Venetoclax
RYDAPT MYLOTARG IDHIFA TIBSOVO REZLID
HIA VENCLEXTA
Oral Intravenous Oral Oral Oral Oral
Strategic Activities
Joins Forces with (June 11, 2024)
in Pioneering Beat AML Trial for New Precision
Therapy.
Grants Orphan Drug Designation to , BVX001 in
AML. (April 17, 2024) and create Ichnos Glenmark
Innovation (IGI) to develop three new oncology
treatments targeting multiple myeloma, Acute
Myeloid Leukemia, solid tumors. (Jan 30,
2024) Acquires s AML Treatment Program ORM-6151
for 180 Million. (Nov 06, 2023) Awards 65
Million to Boost Blood Cancer Research with Focus
on Acute Myeloid Leukemia. (Nov 01,
2023) www.wissenresearch.com